Geneva Partners LLC Sells 2,000 Shares of PerkinElmer, Inc. (PKI)

Geneva Partners LLC decreased its holdings in shares of PerkinElmer, Inc. (NYSE:PKI) by 9.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 19,655 shares of the medical research company’s stock after selling 2,000 shares during the quarter. Geneva Partners LLC’s holdings in PerkinElmer were worth $1,437,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in PKI. Balyasny Asset Management LLC purchased a new stake in PerkinElmer during the second quarter valued at $271,000. Cornerstone Capital Management Holdings LLC. increased its position in PerkinElmer by 37.5% during the second quarter. Cornerstone Capital Management Holdings LLC. now owns 25,886 shares of the medical research company’s stock valued at $1,763,000 after acquiring an additional 7,053 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in PerkinElmer during the second quarter valued at $269,000. Nomura Holdings Inc. bought a new position in PerkinElmer during the second quarter valued at $567,000. Finally, Toronto Dominion Bank increased its position in PerkinElmer by 26.4% during the second quarter. Toronto Dominion Bank now owns 35,925 shares of the medical research company’s stock valued at $2,447,000 after acquiring an additional 7,505 shares during the last quarter. 90.41% of the stock is currently owned by institutional investors.

PerkinElmer, Inc. (NYSE:PKI) opened at $75.46 on Thursday. The company has a quick ratio of 0.90, a current ratio of 1.27 and a debt-to-equity ratio of 0.72. The company has a market cap of $8,180.91, a PE ratio of 28.58, a PEG ratio of 1.71 and a beta of 0.76. PerkinElmer, Inc. has a 1-year low of $53.97 and a 1-year high of $84.49.

PerkinElmer (NYSE:PKI) last posted its quarterly earnings results on Thursday, January 25th. The medical research company reported $0.97 EPS for the quarter, topping the Zacks’ consensus estimate of $0.94 by $0.03. The firm had revenue of $641.63 million for the quarter, compared to analysts’ expectations of $619.14 million. PerkinElmer had a net margin of 12.97% and a return on equity of 13.30%. The business’s revenue for the quarter was up 13.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.83 earnings per share. research analysts predict that PerkinElmer, Inc. will post 3.52 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 10th. Stockholders of record on Friday, April 13th will be issued a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.37%. The ex-dividend date of this dividend is Thursday, April 12th. PerkinElmer’s payout ratio is presently 10.61%.

A number of research analysts have weighed in on PKI shares. Robert W. Baird boosted their price objective on shares of PerkinElmer from $75.00 to $78.00 and gave the company an “outperform” rating in a research report on Friday, November 3rd. Zacks Investment Research upgraded shares of PerkinElmer from a “hold” rating to a “buy” rating and set a $86.00 price objective on the stock in a research report on Monday, January 8th. Morgan Stanley boosted their price objective on shares of PerkinElmer from $77.00 to $78.00 and gave the company an “overweight” rating in a research report on Friday, November 3rd. Jefferies Group reiterated a “hold” rating and set a $70.00 price objective on shares of PerkinElmer in a research report on Friday, October 20th. Finally, Cowen reiterated a “hold” rating and set a $84.00 price objective on shares of PerkinElmer in a research report on Friday, January 26th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $76.85.

In other news, insider Frank Anders Wilson sold 37,535 shares of the company’s stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $70.14, for a total value of $2,632,704.90. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Andrew Okun sold 2,324 shares of the company’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $75.44, for a total transaction of $175,322.56. Following the completion of the transaction, the insider now owns 8,876 shares in the company, valued at $669,605.44. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 59,812 shares of company stock worth $4,263,863. Company insiders own 2.20% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Week Herald and is the property of of Week Herald. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://weekherald.com/2018/02/15/geneva-partners-llc-sells-2000-shares-of-perkinelmer-inc-pki.html.

About PerkinElmer

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply